In this issue of the Journal, the group led by Lior Gepstein (1) presents data on the electrophysiological properties of cardiomyocytes (CMCs) derived from induced pluripotent stem cells (iPSCs) of patients affected by catecholaminergic polymorphic ventricular tachycardia (CPVT). The study adds important information on how iPSCs can be used for modeling inherited arrhythmogenic disorders and, perhaps, for developing personalized therapies for these lifethreatening diseases. Here, we will briefly review the amazingly rapid development of iPSC technology and this new important contribution. A step forward in cardiovascular research: iPSC-derived CMCs. Year 2006 will be remembered in science for the first report describing the generation of iPSCs from mouse somatic cells (2) . Ever since, research on iPSCs has exploded. Rapidly, human iPSCs have been generated either by transducing fibroblasts with a combination of retroviruses encoding the original 4 transcription factors (Oct3/4, Sox2, Klf4, and c-Myc) or by an independently determined combination of lentivirally transduced genes (Oct4, Sox2, NANOG, and Lin28) (3, 4) . These human iPSCs are similar to human embryonic stem cells in their morphology and gene expression, and they can differentiate into cell types of the 3 germ layers in vitro and in vivo. Like embryonic stem cells, iPSCs can be used for studies of basic developmental biology. Most importantly, it is possible to generate from iPSCs theoretically unlimited amounts of terminally differentiated cells that can be used for regenerative therapies but also for drug screening or disease modeling (Fig. 1) .
Several investigators have now described methods to differentiate iPSCs into functional CMCs (iPSC-CMCs) ( Fig. 1) (5) . iPSC-CMCs express a large number of cardiacspecific markers, and structural proteins form wellorganized sarcomeres. Both mouse and human iPSCCMCs can generate typical nodal/pacemaker-, atrial-, and ventricular-like action potentials, display physiological adaptation in action potential duration to changes in heart rate, and respond to adrenergic stimulation (6) . Importantly, iPSC-CMCs express ion channels and regulators of intracellular calcium (Ca 2ϩ ) physiology (7). Based on this bulk of scientific evidence, it was rather straightforward to hypothesize that by using this technique, it would have been possible to unravel disease mechanisms underlying the clinical manifestations of several cardiac disorders. Among them, inherited arrhythmogenic disorders certainly represent the ideal model, and it comes as no surprise that they have been the object of very active research. Patient-specific iPSC-CMCs and arrhythmogenic diseases. Patient-specific iPSC-CMCs have been characterized for long-QT syndrome (LQTS) types 1, 2 and 3 (8 -10), for Timothy syndrome (11) , and now also for CPVT (1, 12, 13) .
The first report describing LQTS type 1 patient-specific iPSC-CMCs demonstrated that the cells were able to recapitulate the electrophysiological properties of the disorder: they exhibited prolongation of action potential duration, altered I ks activation and deactivation properties, and abnormal response to catecholamine stimulation that was prevented by beta-blockers (8) . iPSC-CMCs derived from patients affected by LQTS type 2 displayed significant prolongation of the action potential duration due to significant reduction of the I kr current (9) . Most importantly, these iPSC-CMCs revealed marked arrhythmogenicity characterized by early afterdepolarizations and triggered activity. In addition, LQTS type 3 can be modeled using iPSCs (10) . Fibroblasts from knock-in mouse with an in-frame deletion in the SCN5A gene were reprogrammed into iPSCs and then differentiated into iPSC-CMCs that showed delayed inactivation of I Na and prolonged action potential duration. Notably, the action potential duration could be shortened in response to rapid pacing, a behavior now accepted as typical of LQTS type 3 patients and which we had postulated in 1995 (14) a few months after the identification of SCN5A as the disease-gene for LQTS type 3 (15) .
From LQTS, the avalanche of iPSC-CMCs studies now involves another important channelopathy, CPVT. For this disease it is important to remember that coordinated release of Ca 2ϩ from the sarcoplasmic reticulum (SR) through cardiac ryanodine receptor isoform 2 (RYR2) channels is essential for CMCs function. In CPVT, an inherited disease characterized by stress-induced ventricular arrhythmias in young patients with structurally normal hearts (16) , autosomal dominant mutations in RYR2 or recessive mutations in calsequestrin lead to aberrant diastolic Ca 2ϩ release from the SR causing arrhythmogenic delayed afterdepolarizations (DADs). Itzaki et al. (1) report the generation of iPSC-CMCs from a CPVT patient carrying a M4109R heterozygous point RYR2 mutation. In patient-specific iPSC-CMCs, intracellular electrophysiological recording demonstrated the occurrence of DADs in almost 70% of the cells studied compared with a limited 10% in control CMCs. Stimulation of iPSC-CMCs with isoproterenol or forskolin increased both the frequency and the magnitude of DADs and simulated triggered activity. Catecholaminergic stress led to significant whole-cell [Ca 2ϩ ] transient irregularities that improved with the use of beta-blockers. This elegant study by Itzaki et al. represents a promising step forward analyzing in detail the mechanisms involved in the pathophysiology of CPVT and testing the most appropriate therapy according to the disease-causing mutation.
However, the current study is not the very first describing iPSC-CMCs from CPVT patients. Indeed, during the review process of the paper by Itzaki et al. (1), 2 other groups have independently generated, characterized, and reported works on iPSC-CMCs derived from CPVT patients (12, 13) . This coincidence testifies once more to the frenetic activity in the iPSCs field but does not minimize the importance of the work of Itzaki et al. that fully agrees with what has been shown by the other investigators. Jung et al. (13) reported the generation of iPSCs-CMCs from a patient carrying a novel RYR2 S406L mutation. Catecholaminergic stress led to elevated diastolic [Ca 2ϩ ], a reduced SR Ca 2ϩ content, and an increased susceptibility to DADs and arrhythmia compared with control CMCs. These findings were due to increased frequency and duration of elementary Ca 2ϩ release events (Ca 2ϩ sparks). Importantly, the authors were able to show that dantrolene, a drug effective against malignant hyperthermia, restored normal Ca 2ϩ sparks and rescued the arrhythmogenic phenotype. The study from Ofer Binah's group. (12) focused on the form of CPVT caused by the missense mutation D307H in the cardiac calsequestrin gene, CASQ2. The authors demonstrated that iPSCs generated from skin fibroblasts of 2 patients affected by the disease carry the CASQ2 mutation. Next, they generated iPSC-CMCs expressing the mutant CASQ2 protein and showed that the exposure to isoproterenol caused DADs, oscillatory arrhythmic prepotentials, after-contractions, and diastolic [Ca 2ϩ ](i) 
Figure 1 Possible Applications of Patient-Specific iPSC-CMCs
Different types of somatic cells can be reprogrammed to the pluripotent state (iPSCs); using ad hoc differentiation protocols, it is possible to obtain patient-specific cardiomyocytes (iPSC-CMCs) or other differentiated cell types. The possible applications are summarized in the graphic: iPSC-CMCs can be used for regenerative therapies, drug discovery and cardiotoxicity, and for disease modeling. Inherited arrhythmogenic channelopathies were among the first diseases to be investigated by using iPSCCMCs. CPVT ϭ catecholaminergic polymorphic ventricular tachycardia; 2D ϭ 2-dimensional; DAD ϭ delayed afterdepolarization; EB ϭ embryoid body; hiPSCs ϭ humaninduced pluripotent stem cells; LQTS ϭ long-QT syndrome. rise. Interestingly, electron microscopy analysis revealed that, compared with control cells, CPVT iPSC-CMCs had a more immature phenotype with less organized myofibrils, enlarged sarcoplasmic reticulum cisternae, and reduced number of caveolae. Together, these 3 studies strongly support the breakthrough concept that patient-specific iPSC-CMCs can be used to study the electrophysiological mechanisms underlying CPVT. Future directions and limitations. The generation of disease-specific iPSC-CMCs represents an important step forward in cardiovascular research in general, and in the field of cardiac arrhythmias in particular, because human CMCs cannot be routinely isolated from patients. Because of this limitation, up to now heterologous expression in noncardiomyocytes has been used for single-cell electrophysiological and ion channel studies. However, these modified cells fail to reproduce the complex system of CMCs. Furthermore, mouse models are questionable: in mice, the ion channels that contribute to the cardiac action potential are remarkably different from those of humans. Thus, there is great expectation that iPSC-CMCs will allow the unraveling of unsuspected mechanisms underlying the clinical manifestations of inherited arrhythmias. For example, despite recent advances in the comprehension of the genetic basis of LQTS, in 25% of patients with a clear phenotype a genetic defect is not yet identified; this has a negative impact on the clinical management of these patients and of their families because it prevents the very important "cascade" screening (17) . It can be hypothesized that, by using the iPSC-CMCs technology, it will soon be possible to discover typical electrophysiological features that may shed light into the specific disease mechanism and eventually drive a targeted therapeutic strategy. The iPSCCMCs might also be used to clarify the role of modifier genes (18, 19) . Despite all the excitement around iPSCs, there are still several issues that must be solved before this promising technology can be used for clinical purposes. For example, the reprogramming efficiency of somatic cells into iPSCs is still low. Use of small molecules has been proposed to improve the reprogramming efficiency or completely replace 1 or more reprogramming factors (5) . The same approach may also be used to improve the differentiation of iPSCs into CMCs and to push the differentiation to the stage of fully mature CMCs since today we are not quite there. Of relevance, current differentiation strategies lead to the generation of a mix population of nodal/pacemaker-, atrial-, and ventricular-like cells: although the mixed cell population is adequate for some studies, almost pure CMCs are needed for other uses. The most promising methods to enable CMCs identification and isolation are the transgenic selections, that yield a purity of Ͼ90%; it remains to be established if this further genetic modification may affect the characteristics of the iPSC-CMCs. Recently, it has been proposed that epitopes such as EMLIN, SIRPA, and VCAM can be used to successfully sort a fairly homogeneous population of CMCs (20) . Dermal fibroblasts are the cell type most widely used for reprogramming. However, this method requires a skin biopsy, which candidates sometimes refuse. The search for other cell types requiring less invasive procedures for their collection led to the description of circulating CD34 ϩ cells and keratinocytes as suitable sources for cell reprogramming (20) . Also, urinary renal tubular epithelial cells, isolated from patient's urine, have been successfully reprogrammed to iPSCs with high efficiency; the totally noninvasive method to collect them certainly represents a great advantage (21) . Lastly, it is worth noting the urgent need for standardization of the parameters that define iPSCs in general, and iPSC-CMCs in particular, to facilitate the comparison between the results obtained by different groups.
Despite the existence of undeniable problems still requiring solution, it has to be said that the enthusiasm present in many laboratories for the potential implications of iPSCCMCs methods is understandable. Wearing the 2 hats of laboratory and clinical work, we cannot help being cautiously intrigued by this new step toward translational research and totally open-minded about its potential clinical implications.
